Download PDF
Diabetologie und Stoffwechsel 2014; 9(2): R9-R20
DOI: 10.1055/s-0034-1366414
DuS-Refresher
© Georg Thieme Verlag KG Stuttgart · New York

Therapieoptionen des Diabetes mellitus Typ 2 bei hospitalisierten Patienten

T. G. K. Breuer
,
M. S. Abd El Aziz
,
J. J. Meier
Further Information

Publication History

Publication Date:
07 May 2014 (online)

Also available at
    Permissions and Reprints

Corrected by:

Erratum: Therapieoptionen des Diabetes mellitus Typ 2 bei hospitalisierten PatientenDiabetologie und Stoffwechsel 2014; 9(04): 302-302
DOI: 10.1055/s-0034-1385044

Zusammenfassung

Die Therapie des Diabetes mellitus Typ 2 im Krankenhaus stellt nach wie vor eine große Herausforderung für den behandelnden Arzt dar. Die oftmals zahlreichen Komorbiditäten hospitalisierter Patienten mit Diabetes erschweren eine normnahe Blutzuckereinstellung. Durch die kurze Hospitalisationsdauer (7,6 Tage im Jahre 2012) lässt sich eine leitliniengerechte Therapie, die auf langfristige Therapieziele ausgerichtet ist, nicht realisieren. Daher liegt der Fokus der Diabetestherapie im Krankenhaus auf kurzfristigen Behandlungszielen. Es stehen zahlreiche orale Antidiabetika zur Verfügung, deren Verordnung jedoch an die Komorbiditäten des Patienten und mögliche Eingriffe während eines stationären Aufenthalts angepasst werden muss. In terminalen Stadien vieler Begleiterkrankungen wie Nieren- oder Herzinsuffizienzen ist die Einleitung einer Insulintherapie oft unerlässlich. Insgesamt ist für jeden hospitalisierten Patienten zur optimalen Blutzuckereinstellung die Einleitung eines individuellen Therapieregimes nötig, das alle relevanten Begleitumstände berücksichtigt.

Abstract

The treatment of type 2 diabetes mellitus in hospitals still poses a great challenge for the attending physician. The often numerous comorbidities of hospitalized patients with diabetes impede a near normal blood glucose control. Short hospital stays (7.6 days in 2012) limit the application of guidelines, as most guidelines aim at long-term blood glucose control. Thus, diabetes therapy in hospitals focuses on short-term therapeutic goals. Several different glucose-lowering agents are available, but their use must be adjusted to the patient’s comorbidities as well as to possible interventions during the hospital stay. During the terminal stages of many chronic diseases, such as chronic kidney disease or heart failure, initiation of insulin therapy is often indispensable. All in all, optimal blood sugar control necessitates individual therapy regimens, which take into account all relevant circumstances for every patient.

 

  • Literatur

  • 1 Heidemann C, Du Y, Scheidt-Nave C. Wie hoch ist die Zahl der Erwachsenen mit Diabetes in Deutschland. DEGS Symposium am 14.06.2012: Berlin: Robert Koch-Institut; 2012
    Google Scholar
  • 2 Siegel E. Versorgungsstrukturen von Patienten mit Diabetes mellitus in Krankenhäusern. Der Diabetologe 2008; 4: 20-29
    CrossrefGoogle Scholar
  • 3 Fallpauschalenbezogene Krankenhausstatistik (DRG-Statistik). Diagnosen, Proceduren, Fallpauschalen und Case Mix der vollstationären Patientinnen und Patienten in Krankenhäusern. Fallserie 12 Reihe 6.4 DESTATIS: Statistisches Bundesamt; 2011
    Google Scholar
  • 4 Pfeiffer AF, Klein HH. The treatment of type 2 diabetes. Dtsch Arztebl Int 2014; 111: 69-82
    Google Scholar
  • 5 Standards of medical care in diabetes – 2012. Diabetes Care 2012; 35 (Suppl. 01) S11-S63
    CrossrefGoogle Scholar
  • 6 Matthaei S, Bierwirth R, Fritsche A et al. Behandlung des Diabetes mellitus Typ 2. Diabetes und Stoffwechsel 2012; 6 (Suppl. 02) S131-S136
    Google Scholar
  • 7 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379
    CrossrefPubMedGoogle Scholar
  • 8 18,6 Millionen Patienten 2012 stationär im Krankenhaus behandelt. Pressemitteilung DESTATIS: Statistisches Bundesamt; 2013
    Google Scholar
  • 9 van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359-1367
    CrossrefPubMedGoogle Scholar
  • 10 Ling Y, Li X, Gao X. Intensive versus conventional glucose control in critically ill patients: a meta-analysis of randomized controlled trials. Eur J Intern Med 2012; 23: 564-574
    CrossrefGoogle Scholar
  • 11 Lleva RR, Inzucchi SE. Hospital management of hyperglycemia. Curr Opin Endocrinol Diabetes Obes 2011; 18: 110-118
    CrossrefGoogle Scholar
  • 12 Siegmund T. Therapieregister Diabetes für die Klinik. 1. Aufl. Berlin: Lehmanns Media; 2011
    Google Scholar
  • 13 Fachinformationsverzeichnis Deutschland. Frankfurt: Rote Liste® Service GmbH; 2014 Im Internet: http://www.fachinfo.de
    Google Scholar
  • 14 Clement S, Braithwaite SS, Magee MF et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004; 27: 553-591
    CrossrefGoogle Scholar
  • 15 Breuer TGK. Diabetestherapie bei diagnostischen und therapeutischen Eingriffen. In: Nauck MA, Meier JJ, Hrsg. Kursbuch klinische Diabetologie. Mainz: Kirchheim und Co; 2013: 280-284
    Google Scholar
  • 16 Goldberg PA, Siegel MD, Sherwin RS et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care 2004; 27: 461-467
    CrossrefGoogle Scholar
  • 17 Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127-1133
    CrossrefPubMedGoogle Scholar
  • 18 Hasslacher C, Vogt C, Raupp D et al. [Insulin requirement in patients with type 1 diabetes with reduced renal function: human insulin versus analogue insulin]. Dtsch Med Wochenschr 2007; 132: 2500-2504
    Article in Thieme ConnectGoogle Scholar
  • 19 Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia 1984; 27: 351-357
    CrossrefGoogle Scholar
  • 20 Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA et al. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009; 15: 280-288
    CrossrefGoogle Scholar
  • 21 Petrides AS, Vogt C, Schulze-Berge D et al. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19: 616-627
    CrossrefGoogle Scholar
  • 22 Petrides AS, Stanley T, Matthews DE et al. Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity. Hepatology 1998; 28: 141-149
    CrossrefGoogle Scholar
  • 23 Brackett CC. Clarifying metformin’s role and risks in liver dysfunction. J Am Pharm Assoc (2003) 2010; 50: 407-410
    CrossrefGoogle Scholar
  • 24 Musso G, Cassader M, Rosina F et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012; 55: 885-904
    CrossrefGoogle Scholar
  • 25 Sjoberg RJ, Kidd GS. Pancreatic diabetes mellitus. Diabetes Care 1989; 12: 715-724
    CrossrefGoogle Scholar
  • 26 Schrader H, Menge BA, Schneider S et al. Reduced pancreatic volume and beta-cell area in patients with chronic pancreatitis. Gastroenterology 2009; 136: 513-522
    CrossrefGoogle Scholar
  • 27 Larsen S, Hilsted J, Tronier B et al. Metabolic control and B cell function in patients with insulin-dependent diabetes mellitus secondary to chronic pancreatitis. Metabolism 1987; 36: 964-967
    CrossrefGoogle Scholar
  • 28 Permert J, Ihse I, Jorfeldt L et al. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993; 159: 101-107
    Google Scholar
  • 29 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
    CrossrefGoogle Scholar
  • 30 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865
    CrossrefGoogle Scholar
  • 31 Bell DS. Do sulfonylurea drugs increase the risk of cardiac events?. CMAJ 2006; 174: 185-186
    CrossrefGoogle Scholar
  • 32 Meier JJ, Gallwitz B, Schmidt WE et al. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?. Heart 2004; 90: 9-12
    CrossrefGoogle Scholar
  • 33 Nauck MA, Vilsboll T, Gallwitz B et al. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009; 32 (Suppl. 02) S223-S231
    CrossrefGoogle Scholar
  • 34 Engel SS, Round E, Golm GT et al. Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther 2013; 4: 119-145
    CrossrefGoogle Scholar
  • 35 White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335
    CrossrefGoogle Scholar
  • 36 Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326
    CrossrefGoogle Scholar
  • 37 Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34: 29-34
    CrossrefGoogle Scholar
  • 38 Eurich DT, Weir DL, Majumdar SR et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 2013; 6: 395-402
    CrossrefGoogle Scholar
  • 39 Sokos GG, Nikolaidis LA, Mankad S et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006; 12: 694-699
    CrossrefGoogle Scholar
  • 40 Umpierrez GE, Smiley D, Zisman A et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007; 30: 2181-2186
    CrossrefGoogle Scholar
  • 41 Umpierrez GE, Smiley D, Jacobs S et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011; 34: 256-261
    CrossrefGoogle Scholar